Bruce Booth - 09 Jul 2024 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
09 Jul 2024, 17:15:28 UTC
Prior SEC filing
20 Jun 2024
Next SEC filing
06 Feb 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ommer Chohan, Attorney-in-Fact
Filing notes and source

Key filing fact

Bruce Booth filed Form 4 for Kymera Therapeutics, Inc. (KYMR) on 09 Jul 2024.

Key facts

  • This page summarizes Bruce Booth's Form 4 filing for Kymera Therapeutics, Inc. (KYMR).
  • 10 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 09 Jul 2024, 17:15.

Change

  • Previous filing in this sequence was filed on 20 Jun 2024.
  • Current net transaction value: -$17,346,919.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KYMR transaction

Common Stock

Sale

Transaction value
$869,651
Shares
-24,449
Change %
-0.54%
Price
$35.57
Shares after
4,523,951
Date
09 Jul 2024
Ownership
See footnote
Footnotes
F1, F2, F3
KYMR transaction

Common Stock

Sale

Transaction value
$1,045,335
Shares
-28,718
Change %
-0.63%
Price
$36.40
Shares after
4,495,233
Date
09 Jul 2024
Ownership
See footnote
Footnotes
F1, F3, F4
KYMR transaction

Common Stock

Sale

Transaction value
$1,562,354
Shares
-41,763
Change %
-0.93%
Price
$37.41
Shares after
4,453,470
Date
09 Jul 2024
Ownership
See footnote
Footnotes
F1, F3, F5
KYMR transaction

Common Stock

Sale

Transaction value
$7,075,241
Shares
-183,868
Change %
-4.1%
Price
$38.48
Shares after
4,269,602
Date
09 Jul 2024
Ownership
See footnote
Footnotes
F1, F3, F6
KYMR transaction

Common Stock

Sale

Transaction value
$3,784,114
Shares
-96,386
Change %
-2.3%
Price
$39.26
Shares after
4,173,216
Date
09 Jul 2024
Ownership
See footnote
Footnotes
F1, F3, F7
KYMR transaction

Common Stock

Sale

Transaction value
$182,581
Shares
-5,133
Change %
-0.64%
Price
$35.57
Shares after
796,889
Date
09 Jul 2024
Ownership
See footnote
Footnotes
F2, F8, F9
KYMR transaction

Common Stock

Sale

Transaction value
$219,492
Shares
-6,030
Change %
-0.76%
Price
$36.40
Shares after
790,859
Date
09 Jul 2024
Ownership
See footnote
Footnotes
F4, F8, F9
KYMR transaction

Common Stock

Sale

Transaction value
$328,048
Shares
-8,769
Change %
-1.1%
Price
$37.41
Shares after
782,090
Date
09 Jul 2024
Ownership
See footnote
Footnotes
F5, F8, F9
KYMR transaction

Common Stock

Sale

Transaction value
$1,485,559
Shares
-38,606
Change %
-4.9%
Price
$38.48
Shares after
743,484
Date
09 Jul 2024
Ownership
See footnote
Footnotes
F6, F8, F9
KYMR transaction

Common Stock

Sale

Transaction value
$794,544
Shares
-20,238
Change %
-2.7%
Price
$39.26
Shares after
723,246
Date
09 Jul 2024
Ownership
See footnote
Footnotes
F7, F8, F9
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 9 footnotes

Footnote F1

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.96 to $35.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4), (5), (6) and (7).

Footnote F3

These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.91 inclusive.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.96 inclusive.

Footnote F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.97 to $38.96 inclusive.

Footnote F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.97 to $39.85 inclusive.

Footnote F8

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.

Footnote F9

The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .